Cermin Dunia Kedokteran
Vol 45 No 10 (2018): Muskuloskeletal

Tinjauan atas Ezelin® – Biosimilar Insulin Glargine Pertama di Indonesia

Martinova Sari Panggabean (Medical Department PT. Kalbe Farma, Tbk., Jakarta, Indonesia)



Article Info

Publish Date
01 Oct 2018

Abstract

Diabetes melitus (DM) merupakan suatu kelompok penyakit metabolik dengan karakteristik hiperglikemia karena kelainan sekresi insulin, kinerja insulin atau keduanya. Salah satu terapi diabetes melitus adalah insulin. Tujuan terapi insulin adalah menirukan pola sekresi insulin endogen individu normal. Insulin glargine merupakan insulin basal kerja panjang yang memiliki masa kerja hingga 24 jam dalam mengendalikan glukosa darah puasa. Saat ini telah tersedia insulin basal biosimilar dari insulin glargine. Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Insulin treatment is a component of diabetes treatment. The aim of insulin therapy is to mimic physiologic insulin profile through insulin replacement. Insuline glargine is a long-acting basal insulin which lasts up to 24 hours. Recently, biosimolar insulin glargine has been manufactured and distributed in Indonesia.

Copyrights © 2018






Journal Info

Abbrev

cdk

Publisher

Subject

Health Professions

Description

Cermin Dunia Kedokteran (CDK) is a Medical Journal published since 1974 and affiliated with PT Kalbe Farma Tbk. CDK is intended to help accommodate scientific publications and help increase and disseminate knowledge related to the development of medical science, pharmacy, and public health. CDK ...